Skip to main content
. Author manuscript; available in PMC: 2021 May 26.
Published in final edited form as: Lancet Oncol. 2018 May 31;19(7):889–903. doi: 10.1016/S1470-2045(18)30240-7

Table 4:

Relation between best response to quizartinib and overall survival in all FLT3-ITD-positive patients in cohort 1 and between response to quizartinib, HSCT, and overall survival in all FLT3-ITD-positive patients in cohort 2

Cohort 1
 Cohort 2
Number of
FLT3-ITD-positive
patients (n=112)		 Median overall
survival, weeks
(95% CI)		 Overall survival
of 1 year or
more, n/N (%)		 Number of
FLT3-ITD-positive
patients (n=136)		 Median overall
survival, weeks
(95% CI)		 Bridged to HSCT and
overall survival of
1 year or more, n/N (%)		 Not bridged to HSCT
and overall survival of
1 year or more, n/N (%)
Composite complete remission 63 (56%) 29·7 (24·9–34·7) 12/63 (19%) 62 (46%) 31·1 (24·4–41·7) 10/62 (16%) 8/62 (13%)
 Complete remission 3 (3%) 68·9 (30·6–74·3) 2/3 (67%) 5 (4%) 77·4 (43·0–NR) 0 4/5 (80%)
 Complete remission with incomplete platelet recovery 4 (4%) 54·4 (32·9–NR) 2/4 (50%) 2 (1%) NA* 2/2 (100%) 0
 Complete remission with incomplete haematological recovery 56 (50%) 25·9 (23·7–33·9) 8/56 (14%) 55 (40%) 27·1 (23·3–34·4) 8/55 (15%) 4/55 (7%)
Partial remission 23 (21%) 36·4 (25·–39·9) 4/23 (17%) 39 (29%) 25·9 (19·3–33·0) 7/39 (18%) 1/39 (3%)
No response or unknown response 26 (23%) 10·7 (7·1–15·9) 0 35 (26%) 9·0 (6·1–17·9) 0 1/35 (3%)

Data are n (%), unless otherwise stated. FLT3-ITD=FMS-like tyrosine kinase 3 internal tandem duplication. HSCT=haemopoietic stem cell transplantation. NR=not reached. NA=not applicable.

*

Only two FLT3-ITD-positive patients in cohort 2 had a best response of complete remission with incomplete platelet recovery: one patient died at 83 weeks and the other patient was censored at 105 weeks.